WSLHD
Skip navigation
Please use this identifier to cite or link to this item: https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9455
TitleAnalysis of health-related quality of life and incurred costs among human immunodeficiency virus, tuberculosis, and tuberculosis/HIV coinfected outpatients in Indonesia
Authors: Idrus, L. R.;Fitria, N.;Purba, F. D.;Alffenaar, Jan-Willem C.;Postma, M. J.
WSLHD Author: Alffenaar, Jan-Willem C.
Subjects: Infections;Allied Health
Issue Date: 2024
Citation: Value in Health Regional Issues 41:32-40, 2024
Abstract: OBJECTIVES: A growing interest in healthcare costs and patients' health-related quality of life (HRQoL) exists in the context of the increasing importance of health technology assessment in countries with high numbers of the HIV and tuberculosis (TB) patient populations, such as Indonesia. This study aimed to analyze the HRQoL and out-of-pocket (OOP) costs of HIV, TB, and TB/HIV coinfected participants in a city in Indonesia with a high prevalence of HIV and TB. METHODS: A cross-sectional survey was conducted in the voluntary counseling and testing and lung clinics of Bekasi City Public Hospital (Indonesia) from January to March 2018. Patients' HRQoL was measured using the EQ-5D-5L questionnaire, whereas OOP costs were extracted from a semistructured questionnaire. RESULTS: Of the 460 eligible participants, 82% resided in the city, 48% of them were married, and their median age was 34 years. Less than half were insured, and more than half had no source of income. The median values of health utilities for participants with HIV, TB, and TB/HIV were perceived as potentially high (1.0, 0.9, and 0.8, respectively). The TB/HIV coinfected outpatients had the highest OOP costs (US$94.5), with the largest contribution coming from direct medical OOP expenditures. Taking loans from family members was adopted as a financial strategy to overcome inadequate household incomes and high treatment costs. CONCLUSIONS: This study suggests that TB/HIV coinfection potentially lowers HRQoL and increases healthcare costs and the need for economic analysis to underpin cost-effective treatment in such patients.
URI: https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9455
DOI: https://dx.doi.org/10.1016/j.vhri.2023.10.010
Journal: Value in Health Regional Issues
Type: Journal Article
Study or Trial: Controlled Study
Cross-Sectional Study
Major Clinical Study
Department: Pharmacy
Facility: Westmead
Affiliated Organisations: Unit of PharmacoTherapy, Epidemiology and Economics, Department of Pharmacy, University of Groningen, Groningen, Netherlands
Department of Pharmacy, Bekasi City Public Hospital, West Java, Bekasi City, Indonesia
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Andalas, West Sumatra, Padang, Indonesia
Department of Psychology, Faculty of Psychology, Universitas Padjadjaran, Bandung, Indonesia
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
Westmead Hospital, Sydney, Australia
Sydney Infectious Diseases Institute, University of Sydney, Sydney, Australia
Unit of Global Health, Department of Health Sciences University Medical Centre Groningen Institute of Science in Healthy Ageing and HealthcaRE Department of Economics, Econometrics and Finance, Faculty of Economics and Business, University of Groningen, Groningen, Netherlands
Keywords: coinfection
pharmacoeconomics
tuberculosis
Appears in Collections:Westmead Hospital 2019 - 2024

Files in This Item:
There are no files associated with this item.


Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.